In another cohort study including type 2 diabetes mellitus patients in Hong Kong, SGLT2 inhibitors were found to significantly reduce the risk of new-onset dementia compared to DPP-4 inhibitors. Here, DPP4 is linked to type 2 diabetes mellitus.